A Study of RO4917523 in Patients With Fragile X Syndrome
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will
investigate the efficacy and safety of RO4917523 in adolescent and adult patients with
fragile X syndrome. Patients will be randomized to receive oral doses of 0.5 mg or 1.5 mg of
RO4917523, or matching placebo once daily. The anticipated time on study treatment is 12
weeks.